Cadrenal Therapeutics, Inc. Common StockCVKDNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+133.0%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+133.0%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
12.7x
Strong expansion
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$4.97M+18.2%
2024$4.21M+3.0%
2023$4.08M+938.9%
2022$392859.00-